Key Points
- COO Elizabeth Bhatt sold 4,000 shares on February 18 at an average price of $28.97 for $115,880, reducing her stake by 2.24% to 174,209 shares (≈$5.05M) per the SEC filing.
- SEPN opened at $27.28, has a one‑year range of $4.66–$31.37, a market capitalization of about $1.22 billion and a negative P/E, reflecting its clinical‑stage biotech status.
- Analysts and institutions are largely positive: Septerna has a consensus rating of "Moderate Buy" with an average target of $33.83, several firms initiating buy/strong‑buy coverage, and major institutional inflows including Goldman Sachs raising its stake to 2.7M shares.
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total transaction of $115,880.00. Following the sale, the chief operating officer owned 174,209 shares in the company, valued at approximately $5,046,834.73. This trade represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Septerna Price Performance
Shares of SEPN opened at $27.28 on Friday. Septerna, Inc. has a one year low of $4.66 and a one year high of $31.37. The business's 50 day simple moving average is $26.73 and its 200-day simple moving average is $21.64. The company has a market capitalization of $1.22 billion, a P/E ratio of -18.07 and a beta of 3.85.
Analysts Set New Price Targets
SEPN has been the topic of several analyst reports. Wall Street Zen lowered Septerna from a "strong-buy" rating to a "buy" rating in a research note on Saturday, January 10th. Raymond James Financial started coverage on shares of Septerna in a research note on Friday, December 19th. They issued a "strong-buy" rating and a $38.00 target price for the company. HC Wainwright lifted their price target on shares of Septerna from $30.00 to $35.00 and gave the stock a "buy" rating in a research report on Tuesday, January 20th. JonesTrading assumed coverage on shares of Septerna in a report on Tuesday, December 23rd. They issued a "buy" rating and a $43.00 price target for the company. Finally, Truist Financial started coverage on Septerna in a report on Monday, December 15th. They set a "buy" rating and a $34.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Septerna currently has a consensus rating of "Moderate Buy" and an average target price of $33.83.
Read Our Latest Research Report on SEPN
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. lifted its stake in Septerna by 86.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company's stock valued at $75,698,000 after acquiring an additional 1,260,409 shares during the last quarter. First Light Asset Management LLC acquired a new position in Septerna in the 4th quarter valued at $17,308,000. Primecap Management Co. CA bought a new stake in Septerna in the 4th quarter valued at about $15,225,000. Perceptive Advisors LLC acquired a new stake in shares of Septerna during the 2nd quarter worth $5,723,000. Finally, VR Adviser LLC acquired a new position in Septerna during the second quarter valued at approximately $5,713,000.
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
